Windward Bio prices $175 million IPO

Summary by AI BETAClose X

RTW Biotech notes portfolio company Windward Bio sold 10 million shares at $17 per share for $175 million in a Nasdaq IPO, with Sanofi purchasing $50 million in a concurrent private placement to bring total gross proceeds to $225 million. RTW’s cumulative cost in Windward was $7.0 million and Windward represented 0.8% of RTW’s NAV ($7.4 million) at 31 October 2026; the IPO price implied a 67% step-up to prior holding value and 77% step-up from cost, and Windward closed at $28.50 on debut (up 68%), implying a 180% step-up to prior holding value and 196% step-up from cost.

Disclaimer*

UK 100

Latest directors dealings